* CervoMed Inc CRVO.OQ reported a quarterly adjusted loss
of 41
cents per share for the quarter ended in March. The mean
expectation of two analysts for the quarter was for a loss of 39
cents per share. Wall Street expected results to range from -46
cents to -32 cents per share.
* Revenue was $2.35 million; analysts expected $1.35
million.
* CervoMed Inc's reported EPS for the quarter was a loss
of 41
cents.
* The company reported a quarterly loss of $2.51 million.
* CervoMed Inc shares had risen by 4.9% this quarter and
gained 220.4% so far this year.
FORECAST CHANGES
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for CervoMed Inc is
$47.50
This summary was machine generated from LSEG data May 14 at
10:22 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.39 -0.41 Missed
Dec. 31 2023 -0.29 -0.38 Missed
Sep. 30 2023 -0.95 -0.70 Beat